CN109851658B - 一种一步法合成l-肌肽的方法及截短的l-肌肽合成酶 - Google Patents
一种一步法合成l-肌肽的方法及截短的l-肌肽合成酶 Download PDFInfo
- Publication number
- CN109851658B CN109851658B CN201910041416.0A CN201910041416A CN109851658B CN 109851658 B CN109851658 B CN 109851658B CN 201910041416 A CN201910041416 A CN 201910041416A CN 109851658 B CN109851658 B CN 109851658B
- Authority
- CN
- China
- Prior art keywords
- carnosine
- ala
- truncated
- gly
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010087806 Carnosine Proteins 0.000 title claims abstract description 66
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 title claims abstract description 64
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 title claims abstract description 33
- 102000003960 Ligases Human genes 0.000 title claims abstract description 19
- 108090000364 Ligases Proteins 0.000 title claims abstract description 19
- 230000002194 synthesizing effect Effects 0.000 title claims abstract description 11
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims abstract description 38
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract description 36
- 229960002885 histidine Drugs 0.000 claims abstract description 20
- 108020000161 polyphosphate kinase Proteins 0.000 claims abstract description 20
- 229940000635 beta-alanine Drugs 0.000 claims abstract description 19
- 241000588724 Escherichia coli Species 0.000 claims abstract description 17
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims abstract description 13
- 229940044199 carnosine Drugs 0.000 claims abstract description 13
- 102000004190 Enzymes Human genes 0.000 claims abstract description 12
- 108090000790 Enzymes Proteins 0.000 claims abstract description 12
- 150000001413 amino acids Chemical group 0.000 claims abstract description 8
- 238000005859 coupling reaction Methods 0.000 claims abstract description 8
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims abstract description 7
- 230000008878 coupling Effects 0.000 claims abstract description 7
- 238000010168 coupling process Methods 0.000 claims abstract description 7
- 238000006911 enzymatic reaction Methods 0.000 claims abstract description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims abstract description 7
- 229920000388 Polyphosphate Polymers 0.000 claims abstract description 6
- 239000001205 polyphosphate Substances 0.000 claims abstract description 6
- 235000011176 polyphosphates Nutrition 0.000 claims abstract description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 5
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 claims abstract description 4
- 239000012190 activator Substances 0.000 claims abstract description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 238000003259 recombinant expression Methods 0.000 claims description 8
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 claims description 6
- 235000019982 sodium hexametaphosphate Nutrition 0.000 claims description 6
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 claims description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 108020004705 Codon Proteins 0.000 claims description 3
- 102000001253 Protein Kinase Human genes 0.000 claims description 3
- 241001052560 Thallis Species 0.000 claims description 3
- 230000003197 catalytic effect Effects 0.000 claims description 3
- 238000007036 catalytic synthesis reaction Methods 0.000 claims description 3
- 229930027917 kanamycin Natural products 0.000 claims description 3
- 229960000318 kanamycin Drugs 0.000 claims description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 3
- 229930182823 kanamycin A Natural products 0.000 claims description 3
- 238000005457 optimization Methods 0.000 claims description 3
- 241001646716 Escherichia coli K-12 Species 0.000 claims description 2
- 239000001888 Peptone Substances 0.000 claims description 2
- 108010080698 Peptones Proteins 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 235000019319 peptone Nutrition 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 1
- 108030007222 Carnosine synthases Proteins 0.000 claims 1
- 241000287828 Gallus gallus Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000012136 culture method Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 11
- 230000008569 process Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000008929 regeneration Effects 0.000 abstract description 3
- 238000011069 regeneration method Methods 0.000 abstract description 3
- 125000004122 cyclic group Chemical group 0.000 abstract description 2
- 230000030609 dephosphorylation Effects 0.000 abstract description 2
- 238000006209 dephosphorylation reaction Methods 0.000 abstract description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 abstract description 2
- 238000000746 purification Methods 0.000 abstract description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 239000012634 fragment Substances 0.000 description 7
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004400 Aminopeptidases Human genes 0.000 description 3
- 108090000915 Aminopeptidases Proteins 0.000 description 3
- 108010079364 N-glycylalanine Proteins 0.000 description 3
- 108010047495 alanylglycine Proteins 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 108010090894 prolylleucine Proteins 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- VGPWRRFOPXVGOH-BYPYZUCNSA-N Ala-Gly-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)NCC(O)=O VGPWRRFOPXVGOH-BYPYZUCNSA-N 0.000 description 2
- MQIGTEQXYCRLGK-BQBZGAKWSA-N Ala-Gly-Pro Chemical compound C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O MQIGTEQXYCRLGK-BQBZGAKWSA-N 0.000 description 2
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 2
- CVLIHKBUPSFRQP-WHFBIAKZSA-N Cys-Gly-Ala Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](C)C(O)=O CVLIHKBUPSFRQP-WHFBIAKZSA-N 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 241000287826 Gallus Species 0.000 description 2
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 2
- JQFILXICXLDTRR-FBCQKBJTSA-N Gly-Thr-Gly Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)NCC(O)=O JQFILXICXLDTRR-FBCQKBJTSA-N 0.000 description 2
- MYXNLWDWWOTERK-BHNWBGBOSA-N Gly-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN)O MYXNLWDWWOTERK-BHNWBGBOSA-N 0.000 description 2
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 2
- 229960001280 amantadine hydrochloride Drugs 0.000 description 2
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- -1 amino, carboxyl Chemical group 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 2
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 108010057821 leucylproline Proteins 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000006340 racemization Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DXXHRZUOTPMGEH-UHFFFAOYSA-N 3-(1,3-dioxoisoindol-2-yl)propanoic acid Chemical compound C1=CC=C2C(=O)N(CCC(=O)O)C(=O)C2=C1 DXXHRZUOTPMGEH-UHFFFAOYSA-N 0.000 description 1
- SBGXWWCLHIOABR-UHFFFAOYSA-N Ala Ala Gly Ala Chemical compound CC(N)C(=O)NC(C)C(=O)NCC(=O)NC(C)C(O)=O SBGXWWCLHIOABR-UHFFFAOYSA-N 0.000 description 1
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 1
- VBDMWOKJZDCFJM-FXQIFTODSA-N Ala-Ala-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N VBDMWOKJZDCFJM-FXQIFTODSA-N 0.000 description 1
- DECCMEWNXSNSDO-ZLUOBGJFSA-N Ala-Cys-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O DECCMEWNXSNSDO-ZLUOBGJFSA-N 0.000 description 1
- ZVFVBBGVOILKPO-WHFBIAKZSA-N Ala-Gly-Ala Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O ZVFVBBGVOILKPO-WHFBIAKZSA-N 0.000 description 1
- IPZQNYYAYVRKKK-FXQIFTODSA-N Ala-Pro-Ala Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IPZQNYYAYVRKKK-FXQIFTODSA-N 0.000 description 1
- ADSGHMXEAZJJNF-DCAQKATOSA-N Ala-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N ADSGHMXEAZJJNF-DCAQKATOSA-N 0.000 description 1
- XWFWAXPOLRTDFZ-FXQIFTODSA-N Ala-Pro-Ser Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O XWFWAXPOLRTDFZ-FXQIFTODSA-N 0.000 description 1
- DCVYRWFAMZFSDA-ZLUOBGJFSA-N Ala-Ser-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DCVYRWFAMZFSDA-ZLUOBGJFSA-N 0.000 description 1
- NZGRHTKZFSVPAN-BIIVOSGPSA-N Ala-Ser-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N NZGRHTKZFSVPAN-BIIVOSGPSA-N 0.000 description 1
- WNHNMKOFKCHKKD-BFHQHQDPSA-N Ala-Thr-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O WNHNMKOFKCHKKD-BFHQHQDPSA-N 0.000 description 1
- IOFVWPYSRSCWHI-JXUBOQSCSA-N Ala-Thr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)N IOFVWPYSRSCWHI-JXUBOQSCSA-N 0.000 description 1
- 108010085443 Anserine Proteins 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- AEJSNWMRPXAKCW-WHFBIAKZSA-N Cys-Ala-Gly Chemical compound SC[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O AEJSNWMRPXAKCW-WHFBIAKZSA-N 0.000 description 1
- WVLZTXGTNGHPBO-SRVKXCTJSA-N Cys-Leu-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O WVLZTXGTNGHPBO-SRVKXCTJSA-N 0.000 description 1
- KSMSFCBQBQPFAD-GUBZILKMSA-N Cys-Pro-Pro Chemical compound SC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 KSMSFCBQBQPFAD-GUBZILKMSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- QXPRJQPCFXMCIY-NKWVEPMBSA-N Gly-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN QXPRJQPCFXMCIY-NKWVEPMBSA-N 0.000 description 1
- XPJBQTCXPJNIFE-ZETCQYMHSA-N Gly-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)CN XPJBQTCXPJNIFE-ZETCQYMHSA-N 0.000 description 1
- FQKKPCWTZZEDIC-XPUUQOCRSA-N Gly-His-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 FQKKPCWTZZEDIC-XPUUQOCRSA-N 0.000 description 1
- YFGONBOFGGWKKY-VHSXEESVSA-N Gly-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)CN)C(=O)O YFGONBOFGGWKKY-VHSXEESVSA-N 0.000 description 1
- SWQALSGKVLYKDT-UHFFFAOYSA-N Gly-Ile-Ala Natural products NCC(=O)NC(C(C)CC)C(=O)NC(C)C(O)=O SWQALSGKVLYKDT-UHFFFAOYSA-N 0.000 description 1
- PAWIVEIWWYGBAM-YUMQZZPRSA-N Gly-Leu-Ala Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O PAWIVEIWWYGBAM-YUMQZZPRSA-N 0.000 description 1
- QSQXZZCGPXQBPP-BQBZGAKWSA-N Gly-Pro-Cys Chemical compound C1C[C@H](N(C1)C(=O)CN)C(=O)N[C@@H](CS)C(=O)O QSQXZZCGPXQBPP-BQBZGAKWSA-N 0.000 description 1
- AIPUZFXMXAHZKY-QWRGUYRKSA-N His-Leu-Gly Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AIPUZFXMXAHZKY-QWRGUYRKSA-N 0.000 description 1
- ZVKDCQVQTGYBQT-LSJOCFKGSA-N His-Pro-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O ZVKDCQVQTGYBQT-LSJOCFKGSA-N 0.000 description 1
- 108010025076 Holoenzymes Proteins 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- CMNMPCTVCWWYHY-MXAVVETBSA-N Ile-His-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(C)C)C(=O)O)N CMNMPCTVCWWYHY-MXAVVETBSA-N 0.000 description 1
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 1
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 description 1
- CCLQKVKJOGVQLU-QMMMGPOBSA-N L-homocarnosine Chemical compound NCCCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 CCLQKVKJOGVQLU-QMMMGPOBSA-N 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 1
- IASQBRJGRVXNJI-YUMQZZPRSA-N Leu-Cys-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)NCC(O)=O IASQBRJGRVXNJI-YUMQZZPRSA-N 0.000 description 1
- CCQLQKZTXZBXTN-NHCYSSNCSA-N Leu-Gly-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O CCQLQKZTXZBXTN-NHCYSSNCSA-N 0.000 description 1
- HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 1
- HYMLKESRWLZDBR-WEDXCCLWSA-N Leu-Gly-Thr Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O HYMLKESRWLZDBR-WEDXCCLWSA-N 0.000 description 1
- FLNPJLDPGMLWAU-UWVGGRQHSA-N Leu-Met-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(C)C FLNPJLDPGMLWAU-UWVGGRQHSA-N 0.000 description 1
- WMIOEVKKYIMVKI-DCAQKATOSA-N Leu-Pro-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WMIOEVKKYIMVKI-DCAQKATOSA-N 0.000 description 1
- UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 1
- DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 description 1
- PWPBLZXWFXJFHE-RHYQMDGZSA-N Leu-Pro-Thr Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O PWPBLZXWFXJFHE-RHYQMDGZSA-N 0.000 description 1
- IRMLZWSRWSGTOP-CIUDSAMLSA-N Leu-Ser-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O IRMLZWSRWSGTOP-CIUDSAMLSA-N 0.000 description 1
- ADJWHHZETYAAAX-SRVKXCTJSA-N Leu-Ser-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N ADJWHHZETYAAAX-SRVKXCTJSA-N 0.000 description 1
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 1
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- IUYCGMNKIZDRQI-BQBZGAKWSA-N Met-Gly-Ala Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O IUYCGMNKIZDRQI-BQBZGAKWSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 241000210053 Potentilla elegans Species 0.000 description 1
- IFMDQWDAJUMMJC-DCAQKATOSA-N Pro-Ala-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O IFMDQWDAJUMMJC-DCAQKATOSA-N 0.000 description 1
- HAAQQNHQZBOWFO-LURJTMIESA-N Pro-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1 HAAQQNHQZBOWFO-LURJTMIESA-N 0.000 description 1
- KDBHVPXBQADZKY-GUBZILKMSA-N Pro-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KDBHVPXBQADZKY-GUBZILKMSA-N 0.000 description 1
- CZCCVJUUWBMISW-FXQIFTODSA-N Pro-Ser-Cys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O CZCCVJUUWBMISW-FXQIFTODSA-N 0.000 description 1
- AIOWVDNPESPXRB-YTWAJWBKSA-N Pro-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2)O AIOWVDNPESPXRB-YTWAJWBKSA-N 0.000 description 1
- BRKHVZNDAOMAHX-BIIVOSGPSA-N Ser-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N BRKHVZNDAOMAHX-BIIVOSGPSA-N 0.000 description 1
- CKDXFSPMIDSMGV-GUBZILKMSA-N Ser-Pro-Val Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O CKDXFSPMIDSMGV-GUBZILKMSA-N 0.000 description 1
- PMTWIUBUQRGCSB-FXQIFTODSA-N Ser-Val-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O PMTWIUBUQRGCSB-FXQIFTODSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- BSNZTJXVDOINSR-JXUBOQSCSA-N Thr-Ala-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O BSNZTJXVDOINSR-JXUBOQSCSA-N 0.000 description 1
- XSLXHSYIVPGEER-KZVJFYERSA-N Thr-Ala-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XSLXHSYIVPGEER-KZVJFYERSA-N 0.000 description 1
- SLUWOCTZVGMURC-BFHQHQDPSA-N Thr-Gly-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O SLUWOCTZVGMURC-BFHQHQDPSA-N 0.000 description 1
- FDALPRWYVKJCLL-PMVVWTBXSA-N Thr-His-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)NCC(O)=O FDALPRWYVKJCLL-PMVVWTBXSA-N 0.000 description 1
- QNXZCKMXHPULME-ZNSHCXBVSA-N Thr-Val-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O QNXZCKMXHPULME-ZNSHCXBVSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- LAYSXAOGWHKNED-XPUUQOCRSA-N Val-Gly-Ser Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LAYSXAOGWHKNED-XPUUQOCRSA-N 0.000 description 1
- ZHQWPWQNVRCXAX-XQQFMLRXSA-N Val-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZHQWPWQNVRCXAX-XQQFMLRXSA-N 0.000 description 1
- HPOSMQWRPMRMFO-GUBZILKMSA-N Val-Pro-Cys Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)O)N HPOSMQWRPMRMFO-GUBZILKMSA-N 0.000 description 1
- DEGUERSKQBRZMZ-FXQIFTODSA-N Val-Ser-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DEGUERSKQBRZMZ-FXQIFTODSA-N 0.000 description 1
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 108010082286 glycyl-seryl-alanine Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 108700002498 homocarnosine Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- UZCXPYDBYUEZCV-UHFFFAOYSA-N methyl 3-aminopropanoate Chemical compound COC(=O)CCN UZCXPYDBYUEZCV-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 101150001140 ppk gene Proteins 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108700042769 prolyl-leucyl-glycine Proteins 0.000 description 1
- 108010093296 prolyl-prolyl-alanine Proteins 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 108010053725 prolylvaline Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 201000008525 senile cataract Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Landscapes
- Enzymes And Modification Thereof (AREA)
Abstract
本发明公开了一种一步法合成L‑肌肽的方法及截短的L‑肌肽合成酶,该方法以β‑丙氨酸、L‑组氨酸、ATP和聚磷酸盐为原料,MgCl2为激活剂,加入L‑肌肽合成酶和聚磷酸盐激酶,在pH 6.5‑8.5,30‑45℃温度条件下通过酶促反应偶联催化合成肌肽;本发明利用大肠杆菌分别表达截短的L‑肌肽合成酶(其氨基酸序列如SEQ ID No.3所示)和聚磷酸盐激酶,经纯化后混合形成双酶偶联体系,截短表达的L‑肌肽合成酶催化β‑丙氨酸和L‑组氨酸合成L‑肌肽,同时伴随着ATP去磷酸化形成ADP,聚磷酸盐激酶则催化聚磷酸盐转磷酸基团给ADP形成ATP,从而实现ATP的循环再生;利用双酶偶联体系,在合适的反应条件下反应得到肌肽;本发明的方法具有原料价格低廉、酶转化时间短、操作简便以及生产成本低等优点。
Description
技术领域
本发明涉及一种肌肽的制备方法,具体是一种一步法合成L-肌肽的方法,属于生物生产技术领域。
背景技术
L-肌肽(β-丙氨酰-L-组氨酸)及其类似物(如高肌肽和鹅肌肽),是广泛存在于哺乳动物的大脑、肌肉和其他重要组织中的天然活性二肽。自该活性肽发现的一百多年来,已有大量的研究发现或者证明L-肌肽具有显著的抗氧化、消除胞内自由基、抗衰老等活性,并且在临床上用于高血压、心脏病、老年性白内障、溃疡、抗肿瘤、促进伤口愈合等方面的辅助治疗。由于其抗氧化的活性强,毒副作用低并具有多种生理活性,该活性肽及其衍生物在医药、保健、卫生、化妆品等领域已有广泛的应用,市场空间广阔。
目前L-肌肽的生产主要采用化学合成法。已有的化学合成方法比较多,主要可以分为两大类:(1)利用β-丙氨酸参与合成。其主要路线是β-丙氨酸经氨基保护、羧基活化后与保护的L-组氨酸缩合,然后脱掉保护基团得到L-肌肽。该路线由于各个保护基团的差异导致合成路线较多。其中常用的方法是利用邻苯二甲酸酐与β-丙氨酸生成邻苯二甲酰-β-丙氨酸保护氨基,羧基与氯化亚砜反应生成邻苯二甲酰-β-丙氨酰氯,再与保护的L-组氨酸形成肽键后脱保护基团得到产品。该路线比较复杂,收率低,肽键形成过程中易消旋,影响产品纯度,并且溶剂消耗大,易造成环境污染;(2)无β-丙氨酸参与的反应:主要原理为L-组氨酸先与不同的β-丙氨酸前体生成肽键,再进一步转换为肌肽。常用的路线是在醇钠作用下,L-组氨酸和氰乙酸乙酯发生酰化反应,得到氰基乙酰-L-组氨酸,经催化氢化还原得L-肌肽。该路线相对简单,省去对不同基团的保护和脱保护的过程,避免消旋反应的发生,但是需要无水操作,要求严格。同时,氰乙酸乙酯为环境毒害物质,易引起水体污染和毒性反应。
目前,已有采用温和环保的酶催化合成取代传统化学合成工艺的报道。如采用氨肽酶催化β-丙氨酸甲酯与L-组氨酸一步合成L-肌肽(申请公布号为CN107217048A的专利文献)。该方法依然需要将β丙氨酸甲酯化,并且反应液中合成的L-肌肽会被氨肽酶降解为β-丙氨酸和L-组氨酸,同时,氨肽酶会形成三肽,导致反应产物复杂、提取纯化困难、L-肌肽得率较低。
发明内容
本发明的目的是提供一种一步法合成L-肌肽的方法,该方法具有原料价格低廉、酶转化时间短、操作简便以及生产成本低等优点,具有较好的工业应用潜力。
为了达到上述技术目的,本发明的技术方案是:
一种一步法合成L-肌肽的方法,该方法以β-丙氨酸、L-组氨酸、ATP和聚磷酸盐为原料,MgCl2为激活剂,加入L-肌肽合成酶和聚磷酸盐激酶,在pH6.5-8.5,30-45℃温度条件下通过酶促反应偶联催化合成肌肽。
具体地,包括以下步骤:
(1)分别构建截短的L-肌肽合成酶基因重组表达载体pET-CARNS1和聚磷酸盐激酶基因重组表达载体pET-Ppk;其中,所述截短的L-肌肽合成酶基因来源于Gallus gallus,将该序列经密码子优化后其核苷酸序列为SEQ ID NO.1所示序列;聚磷酸盐激酶基因来源于E.coli K-12(MG1655),其核苷酸序列为SEQ ID NO.2所示;截短的L-肌肽合成酶氨基酸序列如SEQ ID NO.3所示。
(2)分别将步骤(1)中的重组表达载体转化至大肠杆菌E.coli BL21(DE3),获得基因工程重组菌株E.coli pET-CARNS1和E.coli PET-PPK。
(3)培养步骤(2)中的重组菌株,从而获得表达截短的L-肌肽合成酶和聚磷酸盐激酶的菌体。
重组菌株的培养方法为:重组菌株按体积百分比的1-2%接种至含50μg/mL卡那霉素的LB液体培养基中,于37℃,180-220rpm培养至OD600达到0.6-0.8时,添加终浓度0.2-0.5mM IPTG,于25-28℃诱导培养8-10h,收集菌体。
作为优选,所述LB液体培养基每升包括10g氯化钠、5g酵母粉、10g蛋白胨,pH值为7.2-7.4。
(4)破碎步骤(3)中的菌体获得粗酶液,经镍柱纯化后混合。
(5)将步骤(4)中获得的混合酶液加入含有80-150mMβ-丙氨酸、80-150mM L-组氨酸、5mM MgCl2、3.0-6.0mM ATP和30-50mM六偏磷酸钠的催化液中,在pH值为6.5-8.5,温度为30-45℃条件下进行酶促反应合成肌肽。
所述催化液为50mM磷酸缓冲液中含有浓度为100mMβ-丙氨酸、100mM L-组氨酸、5mM MgCl2、5mM ATP和50mM六偏磷酸钠。
本发明方法利用大肠杆菌分别表达截短的L-肌肽合成酶和聚磷酸盐激酶,经纯化后混合形成双酶偶联体系。截短表达的L-肌肽合成酶催化β-丙氨酸和L-组氨酸合成L-肌肽,同时伴随着ATP去磷酸化形成ADP,聚磷酸盐激酶则催化聚磷酸盐转磷酸基团给ADP形成ATP,从而实现ATP的循环再生。
肌肽的检测方法为:取适量体积反应液于15000g离心10min后,取上清液经适当稀释后,取30μl样品混于pH值为9.0的270μl 0.2M硼酸缓冲液,加入300μl 1.5mg/ml FMOC-Cl乙腈溶液,室温放置10分钟,再加入300μl4mg/ml盐酸金刚烷胺的乙腈溶液,混匀,乙腈与水比例为1:1,0.22μm滤膜过滤,上HPLC进行测定。
本发明的有益效果:
因来源于Gallus gallus的L-肌肽合成酶全酶不能在大肠杆菌中成功表达。本发明的中设计的截短L-肌肽合成酶基因在大肠杆菌中成功获得可溶性表达,并能一步催化β丙氨酸和L-组氨酸合成L-肌肽。与其它已经报道的酶法或者化学法合成L-肌肽方法相比,本发明所需底物无需经过甲酯化或者基团保护;催化反应中所需要的ATP由聚磷酸激酶催化ADP磷酸化不断再生,只需消耗少量的ADP即可实现ATP的循环再生;且再生原料六偏磷酸钠来源广泛,成本低廉,操作简单,易于规模化生产,具有较好的工业应用潜力。
附图说明
图1为双酶偶联反应示意图。
图2为双酶催化反应液的色谱图和肌肽标准品色谱图。
具体实施方式
下面结合附图和具体实施方式对本发明作进一步详细的说明。
肌肽的制备方法:以β-丙氨酸、L-组氨酸、ATP和聚磷酸盐为原料,MgCl2为激活剂,加入L-肌肽合成酶和聚磷酸盐激酶,在pH 6.5-8.5,30-45℃温度条件下通过酶促反应偶联催化合成肌肽,如图1所示。具体步骤:
一、重组截短L-肌肽合成酶菌株构建
1.1:根据Genbank中基因登录号为GU453679编码的carnosine synthase1的第480到930的氨基酸序列抽提出来,并在氨基酸添加MERKT肽段,形成截短的L-肌肽合成酶氨基酸序列,如SEQ ID NO.3所示,经密码子优化后,在优化序列5’端添加NcoI酶切位点,3’端添加XhoI酶切位点,形成如SEQ ID NO.1所示序列。该序列由生工生物工程(上海)有限公司合成。
1.2:使用限制性内切酶NcoI和XhoI双酶切1.1中的基因片段及pET-28a载体,胶回收目的片段,并用T4DNA连接酶连接两个基因片段,得到重组表达载体pET-CARNS1。
1.3:将1.2中的重组表达载体转化E.coli BL21(DE3)中,获得产截短表达的L-肌肽合成酶菌株E.coli pET-CARNS1。
二、聚磷酸激酶表达菌株构建
2.1:以E.coli K12基因组为模板,用引物对5’-GGATCCATATGGGTCAGGAAAAGCTATAC-3’/5’-CGCGGATCCGGTACCTTATTCAGGTTGTTCGAG-3’扩增ppk基因片段。所述引物分别包含酶切位点NdeI和BamHI,形成如SEQ ID NO.2所示序列。
2.2:使用限制性内切酶NdeI和BamHI双酶切2.1中获得的目的片段及pET-15b载体,胶回收相应目标片段DNA。
2.3:使用T4DNA连接酶连接2.2中的两个基因片段,得到重组载体pET-PPK。
2.4:将2.3获得的重组质粒转化E.coli BL21(DE3)中,获得表达聚磷酸激酶的E.coli PET-PPK。
三、截短L-肌肽合成酶和聚磷酸激酶的制备
将步骤一、二中的菌株分别按照1%或2%(v/v)接种到LB培养基中(含50μg/mL卡那霉素用于E.coli pET-CARNS1,100μg/mL氨苄青霉素用于E.coli pET-PPK),于37℃,200rpm培养至OD600达到0.8左右,添加终浓度为0.4mM的IPTG,25-28℃诱导培养10h。
将E.coli pET-CARNS1发酵液于8000rpm,4℃离心10分钟,收集菌体。使用pH7.4的PBS缓冲液洗涤2次后,再次用缓冲液重悬,加入1%(v/v)Triton-100,冰浴,超声波破碎4秒停2秒,维持15分钟。4℃,12000rpm离心20分钟,取上清液。
将上清液经0.45微米滤膜过滤后,以1ml/min的流速通过Ni Focurose6FF(IMAC)树脂后,用同样流速的0.5M NaCl,20mM pH7.4PBS缓冲液冲洗,再用0.5M NaCl和250mM咪唑溶液以同样流速洗脱目的蛋白。
将洗脱的蛋白用pH7.4PBS缓冲液4℃透析脱盐,获得纯化酶液。
E.coli pET-PPK的发酵液处理方法按照文献(Artificial Cells,BloodSubstitutes,and Biotechnology,34:515–521,2006,DOI:10.1080/10731190600862886)所述进行处理。
四、双酶偶联催化合成L-肌肽
4.1:配置反应体系,其中pH7.4 50mM磷酸缓冲液中含有浓度为100mMβ-丙氨酸、100mM L-组氨酸、5mM MgCl2、5mM ADP和50mM六偏磷酸钠。
4.2:向4.1中添加纯化的L-肌肽合成酶与聚磷酸激酶,使得终浓度分别为0.2mg/ml和0.4mg/ml。反应体系在37℃水浴振荡反应6h。
反应液中L-肌肽及底物氨基酸的检测:上述的L-肌肽制备方法所得催化体系中L-肌肽的检测方法为:取适量体积反应液于15000g离心10min后,取上清液经适当稀释后,取30μl样品混于270μl 0.2M硼酸缓冲液(pH=9.0),加入300μl 1.5mg/ml FMOC-Cl乙腈溶液,室温放置10分钟,再加入300μl4mg/ml盐酸金刚烷胺的乙腈:水(1:1)溶液,混匀,0.22μm滤膜过滤,上HPLC进行测定。
色谱分析条件:Zorbax ODS C18柱,上样量20μl;流动相组成:A:乙腈;B:50mM醋酸钠缓冲液pH4.2;检测波长263nm;流动相总流量1ml/min;柱温30℃;梯度洗脱程序:0-3min,34%A,66%B;3-10min,45%A,55%B;10-20min,60%A,40%B;20-30min,100%A;30-40min,100%A。分析结果如图2所示。
上述实施例不以任何方式限制本发明,凡是采用等同替换或等效变换的方式获得的技术方案均落在本发明的保护范围内。
序列表
<110> 常熟理工学院
<120> 一种一步法合成L-肌肽的方法
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1376
<212> DNA
<213> 原鸡(Gallus gallus)
<400> 1
ccatggagcg taagaccgtc ccgcgtctgc tggctgagtg tctgctgcac cgtgcacaat 60
gccacctggt cgagggtaag gacatcctgc tgatcggtgc cggtggcgtc tctaaaagct 120
tcgtctggga ggcggcacgt gagtacggcc tgcgtatcca cctggtggag agcgacccgg 180
agcacttcgc agcaggtctg gtggaaacct tcctgccgta cgacagccgt gaacaccgtc 240
gcgacgaaga acacgccgaa cgcgtgctgg aaatgctgcg cgcccgtggt ctgcgcccag 300
atgcatgtct gtcctactgg gacgactgcg tggtgctgac ggcactgctg tgtcagcgtc 360
tgggtctgcc tggttgccca ccagcagcag tgcgtctggc aaaacagaaa agccgcaccc 420
accagcacct gcagcgttgc cgtcgtggtc gtccacctcc tgcagcattc tccgtgccat 480
gccgtcgtct gcgttctcac ggtgacgtgg aacgtgcagc tggtgcagtg ccgttcccgg 540
ctgtagctaa actggaattc ggcgcgggtg ctgttggcgt tcgcctggtt gaaaacgcgg 600
gccagtgcca cgctcacgct gctcaactgt ggcacgacct gcgtgctgac gctgaccatc 660
ctggtatcgg cctgggttgg ggtaacgcta tgctgctgat ggaatacgtt ccgggcaccg 720
aacacgatgt agatctggtt ctgttcgaag gccgcctgct gggcgcctgg gttagcgata 780
acggcccgac ccgcgttccg actttcctgg aaactgcggc gactctgccg tcctgcctgc 840
cggcggatcg ccaggctcag ctggttcgtg ctgctctgcg ttgctgccgt gcttgtggtc 900
tgcgtcatgg cgtatttaac gttgaactga aactgtcccc ggcgggcccg cgcctgctgg 960
aaattaaccc gcgcatgggc ggcttctacc tgcgcgattg gatgcgcgcg gtatatggcc 1020
cggatctgct gctggcggcc gttctgctgg cgctgggtct gccgccggtt ctgccgtctc 1080
gtccggcgcc gcgtcaacag ctggcgggtg taatgtgtct ggcgtctgaa catggtcgtg 1140
ccctgcgtgg tggtgtaatg gcggccctgc agggtctgca gcgtcgcggt ctggttcgcc 1200
tgaatccgct gtttgaagaa gcgggtggtc gctatgaaga accgtgtctg tctgttgcct 1260
gtgcgggcga tggcccggcg gaagcgtgcg gccgtctgct gggcctgtgc caggccctgg 1320
gcattgattc tccgcagtat ccggtaggcc attttctgtc ccattttaaa ctcgag 1376
<210> 2
<211> 2067
<212> DNA
<213> 大肠杆菌K-12(mg 1655E.coli K-12 MG 1655)
<400> 2
atgggtcagg aaaagctata catcgaaaaa gagctcagtt ggttatcgtt caatgaacgc 60
gtgcttcagg aagcggcgga caaatctaac ccgctgattg aaaggatgcg tttcctgggg 120
atctattcca ataaccttga tgagttctat aaagtccgct tcgctgaact gaagcgacgc 180
atcattatta gcgaagaaca aggctccaac tctcattccc gccatttact gggcaaaatt 240
cagtcccggg tgctgaaagc cgatcaggaa ttcgacggcc tctacaacga gctattgctg 300
gagatggcgc gcaaccagat cttcctgatt aatgaacgcc agctctccgt caatcaacaa 360
aactggctgc gtcattattt taagcagtat ctgcgtcagc acattacgcc gattttaatc 420
aatcctgaca ctgacttagt gcagttcctg aaagatgatt acacctatct ggcggtggaa 480
attatccgtg gcgataccat ccgttacgcg ctgctggaga tcccatcaga taaagtgccg 540
cgctttgtga atttaccgcc agaagcgccg cgtcgacgca agccgatgat tcttctggat 600
aacattctgc gttactgcct tgatgatatt ttcaaaggct tctttgatta tgacgcgctg 660
aatgcctatt caatgaagat gacccgcgat gccgaatacg atttagtgca tgagatggaa 720
gccagcctga tggagttgat gtcttccagt ctcaagcagc gtttaactgc tgagccggtg 780
cgttttgttt atcagcgcga tatgcccaat gcgctggttg aagtgttacg cgaaaaactg 840
actatttccc gctacgactc catcgtcccc ggcggtcgtt atcataattt taaagacttt 900
attaatttcc ccaatgtcgg caaagccaat ctggtgaaca aaccactgcc gcgtttacgc 960
catatttggt ttgataaagc ccagttccgc aatggttttg atgccattcg cgaacgcgat 1020
gtgttgctct attatcctta tcacaccttt gagcatgtgc tggaactgct gcgtcaggct 1080
tcgttcgacc cgagcgtact ggcgattaaa attaacattt accgcgtggc gaaagattca 1140
cgcatcatcg actcgatgat ccacgccgca cataacggta agaaagtcac cgtggtggtt 1200
gagttacagg cgcgtttcga cgaagaagcc aacattcact gggcgaagcg cctgaccgaa 1260
gcaggcgtgc acgttatctt ctctgcgccg gggctgaaaa ttcacgccaa actgttcctg 1320
atttcacgta aagaaaacgg tgaagtggtg cgttatgcac acatcgggac cgggaacttt 1380
aacgaaaaaa ccgcgcgtct ttatactgac tattcgttgc tgaccgccga tgcgcgcatc 1440
accaacgaag tacggcgggt atttaacttt attgaaaacc cataccgtcc ggtgacattt 1500
gattatttaa tggtatcgcc gcaaaactcc cgccgcctat tgtatgaaat ggtggaccgc 1560
gagatcgcca acgcgcagca agggctgccc agtggtatca ccctgaagct aaataacctt 1620
gtcgataaag gcctggttga tcgtctgtat gcggcctcca gctccggcgt accggttaat 1680
ctgctggttc gcggaatgtg ttcgctgatc cccaatctgg aaggcattag cgacaacatt 1740
cgtgccatca gtattgttga ccgttacctt gaacatgacc gggtttatat ttttgaaaat 1800
ggcggcgata aaaaggtcta cctttcttcc gccgactgga tgacgcgcaa tattgattat 1860
cgtattgaag tggcgacgcc gctgctcgat ccgcgcctga agcagcgggt actggacatc 1920
atcgacatat tgttcagcga tacggtcaaa gcacgttata tcgataaaga actcagtaat 1980
cgctacgttc cccgcggcaa tcgccgcaaa gtacgggcgc agttggcgat ttatgactac 2040
atcaaatcac tcgaacaacc tgaataa 2067
<210> 3
<211> 456
<212> PRT
<213> 原鸡(Gallus gallus)
<400> 3
Met Gly Ala Leu Thr Val Pro Ala Leu Leu Ala Gly Cys Leu Leu His
1 5 10 15
Ala Ala Gly Cys His Leu Val Gly Gly Leu Ala Ile Leu Leu Ile Gly
20 25 30
Ala Gly Gly Val Ser Leu Ser Pro Val Thr Gly Ala Ala Ala Gly Thr
35 40 45
Gly Leu Ala Ile His Leu Val Gly Ser Ala Pro Gly His Pro Ala Ala
50 55 60
Gly Leu Val Gly Thr Pro Leu Pro Thr Ala Ser Ala Gly His Ala Ala
65 70 75 80
Ala Gly Gly His Ala Gly Ala Val Leu Gly Met Leu Ala Ala Ala Gly
85 90 95
Leu Ala Pro Ala Ala Cys Leu Ser Thr Thr Ala Ala Cys Val Val Leu
100 105 110
Thr Ala Leu Leu Cys Gly Ala Leu Gly Leu Pro Gly Cys Pro Pro Ala
115 120 125
Ala Val Ala Leu Ala Leu Gly Leu Ser Ala Thr His Gly His Leu Gly
130 135 140
Ala Cys Ala Ala Gly Ala Pro Pro Pro Ala Ala Pro Ser Val Pro Cys
145 150 155 160
Ala Ala Leu Ala Ser His Gly Ala Val Gly Ala Ala Ala Gly Ala Val
165 170 175
Pro Pro Pro Ala Val Ala Leu Leu Gly Pro Gly Ala Gly Ala Val Gly
180 185 190
Val Ala Leu Val Gly Ala Ala Gly Gly Cys His Ala His Ala Ala Gly
195 200 205
Leu Thr His Ala Leu Ala Ala Ala Ala Ala His Pro Gly Ile Gly Leu
210 215 220
Gly Thr Gly Ala Ala Met Leu Leu Met Gly Thr Val Pro Gly Thr Gly
225 230 235 240
His Ala Val Ala Leu Val Leu Pro Gly Gly Ala Leu Leu Gly Ala Thr
245 250 255
Val Ser Ala Ala Gly Pro Thr Ala Val Pro Thr Pro Leu Gly Thr Ala
260 265 270
Ala Thr Leu Pro Ser Cys Leu Pro Ala Ala Ala Gly Ala Gly Leu Val
275 280 285
Ala Ala Ala Leu Ala Cys Cys Ala Ala Cys Gly Leu Ala His Gly Val
290 295 300
Pro Ala Val Gly Leu Leu Leu Ser Pro Ala Gly Pro Ala Leu Leu Gly
305 310 315 320
Ile Ala Pro Ala Met Gly Gly Pro Thr Leu Ala Ala Thr Met Ala Ala
325 330 335
Val Thr Gly Pro Ala Leu Leu Leu Ala Ala Val Leu Leu Ala Leu Gly
340 345 350
Leu Pro Pro Val Leu Pro Ser Ala Pro Ala Pro Ala Gly Gly Leu Ala
355 360 365
Gly Val Met Cys Leu Ala Ser Gly His Gly Ala Ala Leu Ala Gly Gly
370 375 380
Val Met Ala Ala Leu Gly Gly Leu Gly Ala Ala Gly Leu Val Ala Leu
385 390 395 400
Ala Pro Leu Pro Gly Gly Ala Gly Gly Ala Thr Gly Gly Pro Cys Leu
405 410 415
Ser Val Ala Cys Ala Gly Ala Gly Pro Ala Gly Ala Cys Gly Ala Leu
420 425 430
Leu Gly Leu Cys Gly Ala Leu Gly Ile Ala Ser Pro Gly Thr Pro Val
435 440 445
Gly His Pro Leu Ser His Pro Leu
450 455
Claims (5)
1.一种一步法合成L-肌肽的方法,其特征在于:以β-丙氨酸、L-组氨酸、ATP和聚磷酸盐为原料,MgCl2为激活剂,加入L-肌肽合成酶和聚磷酸盐激酶,在pH 6.5-8.5,30-45 ℃温度条件下通过酶促反应偶联催化合成肌肽;包括以下步骤:
(1)分别构建截短的L-肌肽合成酶基因重组表达载体pET-CARNS1和聚磷酸盐激酶基因重组表达载体pET-Ppk;其中,所述截短的L-肌肽合成酶基因来源于Gallus gallus,将该序列经密码子优化后其核苷酸序列为SEQ ID NO.1所示序列;聚磷酸盐激酶基因来源于E.coli K-12 (MG 1655),其核苷酸序列为SEQ ID NO.2所示;截短的L-肌肽合成酶氨基酸序列如SEQ ID NO.3所示;
(2)分别将步骤(1)中的重组表达载体转化至大肠杆菌E.coli BL21(DE3),获得基因工程重组菌株E.coli pET-CARNS1和E.coli PET-PPK;
(3)培养步骤(2)中的重组菌株,从而获得表达截短的L-肌肽合成酶和聚磷酸盐激酶的菌体;
(4)破碎步骤(3)中的菌体获得粗酶液,经镍柱纯化后混合;
(5)将步骤(4)中获得的混合酶液加入含有80-150 mMβ-丙氨酸、80-150 mM L-组氨酸、5 mM MgCl2、3.0-6.0 mM ADP和30-50 mM六偏磷酸钠的催化液中,在pH值为6.5-8.5,温度为30-45℃条件下进行酶促反应合成肌肽。
2.根据权利要求1所述的一种一步法合成L-肌肽的方法,其特征在于:所述步骤(3)中重组菌株的培养方法为:重组菌株按体积百分比的1-2%接种至含50μg/mL卡那霉素的LB液体培养基中,于37℃,180-220rpm培养至OD600达到0.6-0.8时,添加终浓度0.2-0.5 mMIPTG,于25-28℃诱导培养8-10h,收集菌体。
3.根据权利要求2所述的一种一步法合成L-肌肽的方法,其特征在于:所述LB液体培养基每升包括10g氯化钠、5g酵母粉、10g蛋白胨,pH值为7.2-7.4。
4.根据权利要求1所述的一种一步法合成L-肌肽的方法,其特征在于:所述催化液为50mM磷酸缓冲液中含有浓度为100 mMβ-丙氨酸、100 mM L-组氨酸、5 mM MgCl2、5 mM ADP和50 mM六偏磷酸钠。
5.一种截短的L-肌肽合成酶,其特征在于:其氨基酸序列如SEQ ID NO.3所示。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910041416.0A CN109851658B (zh) | 2019-01-16 | 2019-01-16 | 一种一步法合成l-肌肽的方法及截短的l-肌肽合成酶 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910041416.0A CN109851658B (zh) | 2019-01-16 | 2019-01-16 | 一种一步法合成l-肌肽的方法及截短的l-肌肽合成酶 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109851658A CN109851658A (zh) | 2019-06-07 |
CN109851658B true CN109851658B (zh) | 2021-02-09 |
Family
ID=66895001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910041416.0A Active CN109851658B (zh) | 2019-01-16 | 2019-01-16 | 一种一步法合成l-肌肽的方法及截短的l-肌肽合成酶 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109851658B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110283859A (zh) * | 2019-07-15 | 2019-09-27 | 苏州富士莱医药股份有限公司 | 微生物酶法合成l-肌肽的方法 |
CN113403287B (zh) * | 2021-05-24 | 2024-06-14 | 中国农业大学 | 分离的多肽、核酸及其应用 |
CN113481252A (zh) * | 2021-08-11 | 2021-10-08 | 苏州富士莱医药股份有限公司 | 一步法催化合成l-肌肽的方法 |
CN118043464A (zh) * | 2021-09-30 | 2024-05-14 | 味之素株式会社 | 修饰酶和使用了所述修饰酶的咪唑二肽的制造方法 |
CN114196640B (zh) * | 2021-12-09 | 2024-07-09 | 中国科学院南海海洋研究所 | 一种源于新型贝类的l-肌肽合成酶atpgd及其应用 |
CN115521956B (zh) * | 2022-10-21 | 2024-04-19 | 江苏诚信药业有限公司 | 一种生物酶催化合成l-肌肽的方法 |
CN117486984B (zh) * | 2023-11-07 | 2024-06-21 | 苏州华赛生物工程技术有限公司 | 转运蛋白KefG在提高L-肌肽产量中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105861598A (zh) * | 2016-04-27 | 2016-08-17 | 深圳市古特新生生物科技有限公司 | 一种酶法再生atp的方法及其应用 |
CN109136309B (zh) * | 2017-06-15 | 2023-01-13 | 北京天开易达生物科技有限公司 | 一种利用腺苷代替atp进行酶促反应的生产方法 |
CN107217048A (zh) * | 2017-07-10 | 2017-09-29 | 江苏诚信药业有限公司 | 一种催化合成肌肽的氨肽酶及其制备方法和应用 |
-
2019
- 2019-01-16 CN CN201910041416.0A patent/CN109851658B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN109851658A (zh) | 2019-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109851658B (zh) | 一种一步法合成l-肌肽的方法及截短的l-肌肽合成酶 | |
CN109593805B (zh) | 一种利用l-氨基酸连接酶一步法合成l-肌肽的方法 | |
CN109652484B (zh) | 一种全细胞高效催化合成l-肌肽的方法 | |
CN112980906B (zh) | 一种用于制备β-烟酰胺单核苷酸的酶组合物及其应用 | |
CN108913641B (zh) | 一种重组大肠杆菌及其应用 | |
CN111172127A (zh) | 一种蔗糖磷酸化酶在制备甘油葡萄糖苷中的应用 | |
CN107828714A (zh) | 一株异源表达L‑天冬氨酸‑α‑脱羧酶的大肠杆菌重组菌 | |
CN101165190B (zh) | 固定化双酶法制备n-乙酰神经氨酸 | |
CN113980880B (zh) | 基因工程菌及其应用和以葡萄糖为原料生产阿洛酮糖的方法 | |
CN108690854A (zh) | 一种利用化学-酶法生产l-草铵膦的方法 | |
CN109423469A (zh) | 一种生产葡萄糖醛酸的方法及其专用工程菌 | |
CN111172213B (zh) | 一种用双酶串联制备l-2-氨基丁酸的方法 | |
JP3418764B2 (ja) | エピメラーゼ | |
KR100914525B1 (ko) | 신규 n―아세틸글루코사민―2―에피머라아제 및 이를 이용한 cmp―n―아세틸뉴라민산의 제조방법 | |
CN113754726B (zh) | 一种含多肽标签的重组酶及其在医药化学品合成中的应用 | |
CN109609536B (zh) | 一种全细胞一步合成l-肌肽的方法 | |
RU2453604C1 (ru) | Гибридный белок (варианты), штамм бактерий escherichia coli - продуцент гибридного белка (варианты) и способ получения безметионинового интерферона альфа-2 человека | |
CN111979206B (zh) | 固定化融合酶及用其制备谷胱甘肽的方法 | |
CN107164341A (zh) | 一种植物乳杆菌来源的苯丙酮酸还原酶及应用 | |
CN112342204A (zh) | 一种达比加群中间体的酶催化合成方法及脂肪酶 | |
CN113980925A (zh) | 利用10-去乙酰巴卡亭III 10β-O-乙酰转移酶突变体催化合成紫杉醇及其衍生物 | |
RU2441072C1 (ru) | ГИБРИДНЫЙ БЕЛОК, ШТАММ БАКТЕРИЙ ESCHERICHIA COLI - ПРОДУЦЕНТ ГИБРИДНОГО БЕЛКА И СПОСОБ ПОЛУЧЕНИЯ БЕЗМЕТИОНИНОВОГО ИНТЕРФЕРОНА АЛЬФА-2b ЧЕЛОВЕКА ИЗ ЭТОГО ГИБРИДНОГО БЕЛКА | |
CN113025547A (zh) | 一种胆盐水解酶基因工程菌、胆盐水解酶及其应用 | |
CN102703370A (zh) | 一株组成型表达精氨酸酶的基因工程菌株及其应用 | |
EP4151742B1 (en) | Transgenic cell line and genetically engineered bacterium expressing fructosamine deglycase, and use of fructosamine deglycase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220126 Address after: 215400 Building 1 and 2, No. 98, Zhaoxi Road, Shaxi Town, Taicang City, Suzhou City, Jiangsu Province Patentee after: Suzhou Bainuo Biotechnology Co.,Ltd. Address before: 215500 Changshou City South Three Ring Road No. 99, Suzhou, Jiangsu Patentee before: CHANGSHU INSTITUTE OF TECHNOLOGY |